Pevonedistat, venetoclax and azacitidine for older AML patients

Pevonedistat, azacitidine and venetoclax triplet therapy for AML, MDS and CMMLПодробнее

Venetoclax and azacitidine in older patients with AMLПодробнее

Venetoclax, CLAD/LDAC and azacitdine in older AML patientsПодробнее

Venetoclax for elderly AML patientsПодробнее

The role of venetoclax in older patients with AMLПодробнее

Phase I study of pevonedistat, azacitidine, and venetoclax in patients with R/R AMLПодробнее

Venetoclax plus CLAD/LDAC and aza for older AML patientsПодробнее

A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and AzacitidineПодробнее

Azacitidine, venetoclax & gilteritinib in older/unfit patients with FLT3-mutated AMLПодробнее

IMGN632 plus venetoclax and/or azacitidine for patients with CD123-positive AMLПодробнее

Venetoclax and Azacitidine in Newly Diagnosed AML Patients | Dan Pollyea, MD, MS | ASH 2022 #AMLПодробнее

AML: Managing AEs With Venetoclax + AzacitidineПодробнее

allo-SCT improves survival following venetoclax and azacitidine therapy in AMLПодробнее

Cladribine + LDAC + venetoclax alternated with azacitidine + venetoclax in older patients with AMLПодробнее

Venetoclax and azacitidine for young patients with AMLПодробнее

Oral combination of HMAs + venetoclax in unfit or elderly patients with AMLПодробнее

Venetoclax and azacitidine for AML ineligible for standard inductionПодробнее

VEN-A-QUI: low-dose cytarabine or azacitidine+venetoclax and quizartinib in older patients with AMLПодробнее

Treatment cessation using venetoclax-based therapy for older patients with AMLПодробнее